Literature DB >> 9685852

Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats.

K Matsunaga1, N Yoshimi, Y Yamada, M Shimizu, K Kawabata, Y Ozawa, A Hara, H Mori.   

Abstract

We investigated the modifying effects of nabumetone, a relatively selective cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea(MNU)-induced mammary carcinogenesis in female Sprague-Dawley rats. A total of 124 rats, 6 weeks old, were divided into 6 groups. At 50 days of age, groups 1, 2, and 3 were treated with MNU (50 mg/kg body weight) by subcutaneous injection. From the age of 8 weeks, groups 2 and 4 were given 0.03% nabumetone in the diet and groups 3 and 5 were given 0.03% esculetin in the diet. All rats were necropsied at the termination (25 weeks after the start of experiment). The incidence and multiplicity of neoplasms in group 2 were significantly smaller than those in group 1 (P < 0.005 and P < 0.001, respectively). The incidence of neoplasms in group 3 was also significantly smaller than that in group 1 (P < 0.05). These results indicate that the intake of nabumetone or esculetin during the time corresponding to the post initiation phase has a chemopreventive effect on MNU-induced mammary carcinogenesis in rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685852      PMCID: PMC5921855          DOI: 10.1111/j.1349-7006.1998.tb03289.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  40 in total

1.  Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems.

Authors:  G S Wood; R Warnke
Journal:  J Histochem Cytochem       Date:  1981-10       Impact factor: 2.479

2.  Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids.

Authors:  H Blomgren; G Kling-Andersson
Journal:  Anticancer Res       Date:  1992 May-Jun       Impact factor: 2.480

3.  Altered eicosanoid levels in human colon cancer.

Authors:  B Rigas; I S Goldman; L Levine
Journal:  J Lab Clin Med       Date:  1993-11

4.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.

Authors:  D A Jones; D P Carlton; T M McIntyre; G A Zimmerman; S M Prescott
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

5.  The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone.

Authors:  N Yoshimi; N Ino; M Suzui; T Tanaka; S Nakashima; M Nakamura; Y Nozawa; H Mori
Journal:  Cancer Lett       Date:  1995-10-20       Impact factor: 8.679

6.  Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study.

Authors:  T T Jung; N T Berlinger; S K Juhn
Journal:  Laryngoscope       Date:  1985-03       Impact factor: 3.325

7.  Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats.

Authors:  N Yoshimi; K Kawabata; A Hara; K Matsunaga; Y Yamada; H Mori
Journal:  Jpn J Cancer Res       Date:  1997-11

8.  Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice.

Authors:  S Nakatsugi; M Fukutake; M Takahashi; K Fukuda; T Isoi; Y Taniguchi; T Sugimura; K Wakabayashi
Journal:  Jpn J Cancer Res       Date:  1997-12

9.  Prostaglandins and human lung carcinomas.

Authors:  A Bennett; M A Carroll; I F Stamford; W F Whimster; F Williams
Journal:  Br J Cancer       Date:  1982-12       Impact factor: 7.640

10.  Perspectives on cancer in Japan and the United States.

Authors:  S Broder
Journal:  Jpn J Cancer Res       Date:  1993-08
View more
  6 in total

1.  Esculetin suppresses proliferation of human colon cancer cells by directly targeting β-catenin.

Authors:  Sung-Young Lee; Tae-Gyu Lim; Hanyong Chen; Sung Keun Jung; Hyo-Jeong Lee; Mee-Hyun Lee; Dong Joon Kim; Aram Shin; Ki Won Lee; Ann M Bode; Young-Joon Surh; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-08

2.  Esculetin, a natural coumarin compound, evokes Ca(2+) movement and activation of Ca(2+)-associated mitochondrial apoptotic pathways that involved cell cycle arrest in ZR-75-1 human breast cancer cells.

Authors:  Hong-Tai Chang; Chiang-Ting Chou; You-Sheng Lin; Pochuen Shieh; Daih-Huang Kuo; Chung-Ren Jan; Wei-Zhe Liang
Journal:  Tumour Biol       Date:  2015-10-28

3.  Esculetin, a Coumarin Derivative, Exhibits Anti-proliferative and Pro-apoptotic Activity in G361 Human Malignant Melanoma.

Authors:  Young-Joo Jeon; Jeong-Yun Jang; Jung-Hyun Shim; Pyung Keun Myung; Jung-Il Chae
Journal:  J Cancer Prev       Date:  2015-06

4.  Esculetin Downregulates the Expression of AML1-ETO and C-Kit in Kasumi-1 Cell Line by Decreasing Half-Life of mRNA.

Authors:  Sharad Sawney; Rashi Arora; Kamal K Aggarwal; Daman Saluja
Journal:  J Oncol       Date:  2015-03-11       Impact factor: 4.375

5.  Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19.

Authors:  Gourab Das; Troyee Das; Nilkanta Chowdhury; Durbadal Chatterjee; Angshuman Bagchi; Zhumur Ghosh
Journal:  Genomics       Date:  2020-11-13       Impact factor: 5.736

6.  Toward Multitasking Pharmacological COX-Targeting Agents: Non-Steroidal Anti-Inflammatory Prodrugs with Antiproliferative Effects.

Authors:  Fedora Grande; Francesca Giordano; Maria Antonietta Occhiuzzi; Carmine Rocca; Giuseppina Ioele; Michele De Luca; Gaetano Ragno; Maria Luisa Panno; Bruno Rizzuti; Antonio Garofalo
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.